RELMADA THERAPEUTICS, INC.

Listed Company

RLMDCIK 0001553643NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsNevadaFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-57.39M

Total Assets

$94.00M

Equity

$86.51M

Shares Out

104.89M

Op. Cash Flow

$-45.79M

Business

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company that acquires, develops and advances novel therapeutic candidates. The company’s main programs include Sepranolone (a Phase 2b-ready neurosteroid), NDV-01 (a Phase 2 intravesical controlled‑release gemcitabine/docetaxel formulation), paused esmethadone (REL-1017) for MDD, and a paused psilocybin program including REL-P11. Relmada organizes its operations around drug development, licensing and acquisitions to prioritize mid- to late-stage assets. The company pursues worldwide development and commercialization through clinical trials, in‑licensing and exclusive license agreements, with certain country exclusions in specific deals.

Summary from filing dated 2025-03-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	27	46	55	113	91
General and administrative	32	38	49	48	35
Total operating expenses	59	84	104	161	126
Loss from operations	−59	−84	−104	−161	−126
Interest/investment income, net	1	4	5	—	—
Realized (loss) gain on short-term investments	−79,207	374,926	−4	−585,522	−636,012
Unrealized gain on short-term investments	398,255	6,735	4	−4	−611,382
Total other income (expenses), net	2	4	5	4	−48,317
Net loss	−57	−80	−99	−157	−126
Loss per common share basic (in Dollars per share)	−1.45	−2.65	−3.28	−5.3	−7.16
Loss per common share diluted (in Dollars per share)	−1.45	−2.65	−3.28	−5.3	−7.16
Weighted average number of common shares outstanding basic (in Shares)	39	30	30	30	18
Weighted average number of common shares outstanding diluted (in Shares)	39	30	30	30	18

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	3	4	4	5	44
Short-term investments	90	41	92	143	167
Prepaid expenses	977,721	886,461	1	4	11
Total current assets	94	46	98	153	223
Other assets	19,500	21,975	43,125	34,875	28,293
Total assets	94	46	98	153	223
Accounts payable	2	4	4	5	11
Accrued expenses	5	6	9	7	4
Total current liabilities	6	10	12	12	15
Stock appreciation rights	1	4,467	—	—	—
Total liabilities	7	10	12	12	15
Commitments and Contingencies (Note 10)	—	—	—	—	—
Preferred stock value	—	—	—	—	—
Common stock, $0.001 par value, 150,000,000 shares authorized, 73,333,622 and 30,174,202 shares issued and outstanding, respectively	73,333	30,174	30,099	30,099	27,740
Additional paid-in capital	785	676	646	603	513
Accumulated deficit	−698	−641	−561	−462	−305
Total stockholders equity	87	36	85	140	208
Total liabilities and stockholders equity	94	46	98	153	223

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation	14	30	44	44	40
Stock appreciation rights compensation	1	4,467	—	—	—
Issuance of restricted common stock	905,226	—	—	—	—
Prepaid expenses and other assets	−88,785	319,746	3	7	—
Accounts payable	−3	624,554	−2	421,040	3
Accrued expenses	−1	−3	1	3	−388,560
Net cash used in operating activities	−46	−52	−52	−104	−92
Purchase of short-term investments	−84	−12	−90	−47	—
Sale of short-term investments	36	64	141	67	169
Net cash (used in)/provided by investing activities	−48	52	50	20	−54
Proceeds from issuance of common stock, net	94	—	—	43	185
Payment of ATM fees	−73,021	−287,088	−98,463	—	—
Proceeds from options exercised for common stock	—	246,747	—	703,720	668,431
Net cash provided by/(used in) financing activities	94	−40,341	−98,463	45	188
Net decrease in cash and cash equivalents	−360,486	−234,542	−1	−39	42

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro